Today: 30 April 2026
D-Wave Quantum stock slips as $550 million Quantum Circuits deal puts dilution in focus
9 January 2026
1 min read

D-Wave Quantum stock slips as $550 million Quantum Circuits deal puts dilution in focus

NEW YORK, Jan 8, 2026, 21:16 EST — Trading ended for the session.

  • D-Wave Quantum shares fell 3.1% on Thursday as investors digested its Quantum Circuits acquisition plan
  • The $550 million deal mixes cash and stock, with the share count tied to a price formula and collar
  • Traders are looking to late-January deal timing and the company’s Jan. 27-28 Qubits conference for next details

D-Wave Quantum Inc. (NYSE: QBTS) shares dropped 3.1% on Thursday, continuing declines following its announcement to acquire competitor Quantum Circuits in a cash-and-stock transaction. The stock fluctuated between $28.66 and $30.44, with roughly 38.7 million shares traded.

The acquisition signals a shift to “gate-model” quantum computers, which execute general-purpose quantum algorithms. D-Wave had previously concentrated on quantum annealing, a technique focused on optimization tasks like scheduling. The transaction also places D-Wave in a more competitive field, competing with better-funded rivals and specialized firms for clients and reputation. Barron’s

Timing is crucial for shareholders. Quantum stocks have fluctuated with headlines and hype, and a deal combining new shares with a large cash payment can complicate valuations during volatile trading.

A securities filing showed D-Wave agreed to pay $550 million, including $250 million in cash and $300 million in common stock. The stock portion will be priced using a 10-day volume-weighted average price, or VWAP, with a collar set between $22.30 and $39.03 per share. The deal can be terminated if it does not close by April 6. It remains subject to U.S. antitrust review under the Hart-Scott-Rodino process and requires approval for listing the new shares.

Chief Executive Alan Baratz said the move aims to launch “gate-model products and services” by 2026. D-Wave plans to grow Quantum Circuits’ research in New Haven, Connecticut, with a center led by Yale professor Rob Schoelkopf’s team. The acquisition is set to close in late January. Further details will be shared at the Qubits 2026 user conference on Jan. 27-28 in Boca Raton, Florida. D-Wave Quantum

Rosenblatt Securities raised its price target on D-Wave to $43 from $40 after the acquisition announcement and an investor call, TipRanks reported.

The price collar is as significant as the headline figure. If QBTS trades near the lower bound, the company may issue more shares to meet the $300 million stock portion; if it trades higher, dilution could decrease, up to the established limit.

Execution is crucial, and many quantum ventures falter at this stage. Delays in closing, integration challenges, or product delivery setbacks, combined with a wider risk-off sentiment in volatile tech sectors, could pressure the stock beyond the deal valuation.

D-Wave filed a presentation linked to its Jan. 7 press conference on the deal, offering more details before Friday’s session. Investors are now focused on the late-January closing and the Qubits 2026 conference on Jan. 27-28, where product and revenue updates are expected.

Stock Market Today

  • Is Mosaic (MOS) Undervalued After Recent Price Drop?
    April 30, 2026, 6:49 AM EDT. Mosaic's (MOS) share price fell 21.9% over the past year, amid shifting agriculture market dynamics and sector-wide commodity pressures. A discounted cash flow (DCF) model estimates an intrinsic value of $35.78, suggesting the stock trades at a 35.6% discount to fair value. Mosaic's recent 12-month free cash flow was a negative $487 million, but projections foresee $700 million by 2030. These figures imply potential undervaluation despite recent weakness. Investors are reassessing Mosaic within the materials sector, balancing risks and growth prospects. Traditional valuation via price-to-earnings ratios is less applicable here due to current losses. The stock's underperformance relative to peers and sector sentiment highlights the need for cautious evaluation amid volatile market conditions.

Latest article

Meta Platforms Stock Falls After $145 Billion AI Spending Plan Overshadows Earnings Beat

Meta Platforms Stock Falls After $145 Billion AI Spending Plan Overshadows Earnings Beat

30 April 2026
Meta shares dropped over 6% in after-hours trading as the company raised its 2026 capital expenditure forecast to $125 billion–$145 billion, outpacing investor expectations. First-quarter revenue climbed 33% to $56.31 billion, while net income rose 61% to $26.77 billion. Costs increased 35% to $33.44 billion. Meta ended March with 77,986 employees.
Dow Futures Drop as Oil Shock Threatens Big Tech’s AI Rally

Dow Futures Drop as Oil Shock Threatens Big Tech’s AI Rally

30 April 2026
Dow futures fell 269 points, or 0.6%, early Thursday, while S&P 500 futures slipped 0.1% and Nasdaq 100 futures edged up 0.1%, as rising oil prices offset strong earnings from Alphabet and Amazon. Brent crude climbed on reports President Trump would be briefed on possible military action against Iran. Alphabet reported Q1 revenue up 22% to $109.9 billion; Amazon net sales rose 17% to $181.5 billion.
T. Rowe Price Earnings Today: $13.7 Billion Outflows Put 5% Dividend Stock on the Spot

T. Rowe Price Earnings Today: $13.7 Billion Outflows Put 5% Dividend Stock on the Spot

30 April 2026
T. Rowe Price reported $13.7 billion in first-quarter net outflows and a drop in assets under management to $1.71 trillion at March’s end, down from $1.80 trillion in February. Shares closed at $100.47 on Wednesday and traded at $98.72 premarket. Analysts expect first-quarter EPS between $2.36 and $2.44 on revenue near $1.87 billion. JPMorgan and Barclays cut price targets ahead of the results.
Nebius stock (NBIS) ends higher as Nvidia Rubin rollout news sinks in
Previous Story

Nebius stock (NBIS) ends higher as Nvidia Rubin rollout news sinks in

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom
Next Story

GSK stock slips in London as hepatitis B drug details awaited; Feb 4 results loom

Go toTop